A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.
Papadakis E, Robson N, Yeomans A, Bailey S, Laversin S, Beers S, Sayan AE, Ashton-Key M, Schwaiger S, Stuppner H, Troppmair J, Packham G, Cutress R.
Papadakis E, et al.
Oncotarget. 2016 Apr 5;7(14):18851-64. doi: 10.18632/oncotarget.7944.
Oncotarget. 2016.
PMID: 26958811
Free PMC article.